Cipher Pharmaceuticals to Announce Q3 2025 Financial Results

Cipher Pharmaceuticals ( (TSE:CPH) ) just unveiled an announcement.

Cipher Pharmaceuticals announced the release of its third-quarter 2025 financial results, scheduled for November 6, 2025, followed by a conference call on November 7, 2025, to discuss the results and corporate developments. This announcement is significant for stakeholders as it provides insights into the company’s financial health and strategic direction, potentially impacting its market positioning and investor relations.

The most recent analyst rating on (TSE:CPH) stock is a Buy with a C$16.00 price target. To see the full list of analyst forecasts on Cipher Pharmaceuticals stock, see the TSE:CPH Stock Forecast page.

Spark’s Take on TSE:CPH Stock

According to Spark, TipRanks’ AI Analyst, TSE:CPH is a Outperform.

Cipher Pharmaceuticals’ strong financial performance and record-breaking earnings call results are the most significant factors driving the stock score. However, technical analysis indicates bearish trends, and valuation metrics suggest the stock is fairly valued. Challenges in maintaining profitability and operational efficiency, along with legal costs, slightly temper the overall positive outlook.

To see Spark’s full report on TSE:CPH stock, click here.

More about Cipher Pharmaceuticals

Cipher Pharmaceuticals is a specialty pharmaceutical company with a diverse portfolio of commercial and developmental products, primarily focusing on dermatology. The company acquires products that address unmet medical needs, manages clinical development and regulatory approval, and markets these products in Canada, the U.S., and South America.

Average Trading Volume: 25,414

Technical Sentiment Signal: Strong Buy

Current Market Cap: C$370.7M

Learn more about CPH stock on TipRanks’ Stock Analysis page.